Table 3.

Indications for prescribing denosumab for Bulgarian women with PMO

Indication	Study population (n = 222)
BMD T-score <−2.5 SD	219 (98.6)
History of osteoporotic fracture	49 (22.1)
Multiple risk factors for fracture	45 (20.3)
Intolerant to other PMO therapies	11 (5.0)
Patient preference for convenience and safety	2 (0.9)

Categories as reported to the Bulgarian National Health Insurance Fund; more than one reason could be provided per patient. Data are shown as n (%)

BMD bone mineral density, PMO postmenopausal osteoporosis, SD standard deviation